Stone Bond Technologies EE-LIMS Earns GeneChip-compatible™ Status with the Affymetrix GeneChip® Microarray Platform
News Apr 05, 2006
Stone Bond Technologies has announced that its Enterprise Enabler® and EE-LIMS systems have achieved GeneChip-compatible™ status with the Affymetrix Inc. GeneChip® microarray platform for gene expression and genetic variation analysis in biomedical research and development.
As a GeneChip-compatible software provider and participant in the Affymetrix GeneChip-compatible Applications Program, Stone Bond’s Enterprise Enabler integrates seamlessly with the Affymetrix GeneChip microarray platform.
As a result, laboratories can automate sample data import and test result outflow to and from the Affymetrix GeneChip Operating Software (GCOS) using Stone Bond’s EE-LIMS system, saving time, reducing errors and lowering lab administrative costs.
“Today’s lab manager is under increasing pressure to reduce administrative costs and improve efficiencies and lab economics,” noted Stone Bond President and Chief Executive Officer Antonio Szabo.
“As genetic research becomes more complex, technology that delivers automation compatibility to leverage existing capital investments in the lab provides additive value to streamline operations and help manage research overhead costs.
"We are honored that Affymetrix, the world leader in genetic research technology, has recognized Stone Bond’s EE-LIMS system as a compatible solution to work in partnership with their GeneChip platform.”
“As Affymetrix customers continue to scale up and industrialize their GeneChip microarray experiments for biomedical research, LIMS systems will become more and more important,” said Steve Lincoln, vice president of Informatics at Affymetrix.
“We are pleased to be working with Stone Bond to provide critical data handling and processing in an automated manner.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.